Nanolynx Biologics AG is developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat solid tumors.
Products, services, technology
Nanolynx develops AI-engineered CA-NDCs with 10× deeper tumor penetration and pH-gated tumor-selective activation. Our proprietary IntelliBody™ platform is trained on one of the world's largest nanobody datasets and enables a scalable, multi-program pipeline across validated solid tumor targets.
Cooperation possibilities
We welcome partnerships with pharma, biotech and investors who share our conviction in next-generation solid tumor therapeutics. We are open to research and licensing partnerships and strategic investment to accelerate our CA-NDC programs to in vivo proof-of-concept.
Some insights
We are developing cancer treatments that are safer and more effective for patients with hard-to-treat solid tumors, giving them a better chance at surviving cancer without devastating side effects.
